Creating patient-derived tumor models for head and neck cancer
Official title: Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.
Run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · NCT02572778 · Data updated 2026-11-12
This study is trying to collect tumor samples from patients with head and neck cancer to create models that help test new treatments and understand how these tumors respond to them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain Academic / other |
| Locations | 1 site (Brussels) |
| Status | Recruiting |
| Started | September 2015 |
| Main results expected | December 2025 |
| Study ends | December 2025 |
| Registry record updated | December 3, 2024 |
| Trial ID | NCT02572778 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with primary or recurrent squamous cell carcinoma of the head and neck who can provide informed consent.
✕Probably not a fit
Patients with non-squamous cell carcinoma or those who are not eligible for biopsy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to collect fresh tumor tissue from patients with primary or recurrent head and neck squamous cell carcinoma to establish patient-derived xenograft models. These models will be used to create a biobank representing various tumor subgroups, allowing for genetic and transcriptional profiling. The research will also evaluate the efficacy of new targeted therapies and biomarkers of drug sensitivity, as well as study resistance mechanisms in these tumors. The approach involves local biopsies to obtain the necessary tumor samples.
Why it matters
Potential benefit: If successful, this study could lead to more effective personalized treatment options for patients with head and neck cancer.
How similar studies have gone: Other studies utilizing patient-derived xenografts have shown promise in cancer research, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent * Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available * Follow-up data should be available * Patients with recurrent disease are allowed * Written informed consent
Where it's running
-
Cliniques universitaires Saint-Luc
Brussels, Belgium Recruiting
Study contacts
- Principal investigator: Jean-Pascal Machiels, MD, PhD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: Aline Gillain, MedSciences
- Email: aline.gillain@uclouvain.be
- Phone: 00322764
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ficerafusp alfa plus pembrolizumab before surgery for resectable head and neck squamous cell carcinoma
This trial will test whether giving ficerafusp alfa together with pembrolizumab before surgery helps people with PD‑L1–positive, resectable, high‑risk head and neck squamous cell carcinoma.
-
Cisplatin-related (Ear) Hearing Loss and Balance Issues in Head and Neck Cancer Patients
This observational study tests whether hearing loss, tinnitus, and balance problems occur in head and neck cancer patients treated with cisplatin chemoradiotherapy compared with those receiving only radiotherapy, including optional genetic tests for susceptibility.
-
Injecting a viral particle to treat head and neck cancer
This study is testing a new virus injection to see if it can help treat head and neck cancer in different groups of patients.
-
Understanding the mechanisms behind squamous cell carcinomas
This study is trying to learn more about squamous cell carcinoma by looking at samples from patients to see how certain markers and cells affect the disease and its treatment.
-
Neoadjuvant chemotherapy with a vaccine for HPV-related throat cancer
This study is testing if a new vaccine combined with standard chemotherapy can help people with HPV-related throat cancer live longer and avoid radiation treatment.
-
MRG003 vs cetuximab/methotrexate for RM-SCCHN after prior therapies
This trial tests whether MRG003 can help people with recurrent/metastatic squamous cell carcinoma of the head and neck who have already tried PD-1 inhibitors and platinum therapy by comparing it to cetuximab plus methotrexate as a later-line treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.